PARP inhibitor

Ivy Brain Tumor Center Announces Initial Results of Pamiparib in Newly-Diagnosed and Recurrent Glioblastoma at the European Society for Medical Oncology (ESMO) 2022 Congress

Retrieved on: 
Saturday, September 10, 2022
Hedera, Drug development, Pharmacokinetics, C1-inhibitor, PARP2, MD, BeiGene, Neoplasm, Brain, Clinical trial, Barrow Neurological Institute, Oncology, PARP inhibitor, Protein, CNS, Traffic barrier, Hope, DNA, Glioblastoma, European Society for Medical Oncology, Time, LinkedIn, GLOBE, Instagram, Radiation, DNA repair, GBM, PARP1, Patient, Twitter, PARP, Pharmaceutical industry, Medical imaging, Facebook

The interim analysis demonstrated that pamiparib is well-tolerated in glioblastoma patients, reaches pharmacologically-relevant concentrations in nonenhancing GBM tissue, and sensitizes brain tumor tissue to radiation ex vivo.

Key Points: 
  • The interim analysis demonstrated that pamiparib is well-tolerated in glioblastoma patients, reaches pharmacologically-relevant concentrations in nonenhancing GBM tissue, and sensitizes brain tumor tissue to radiation ex vivo.
  • Nader Sanai, MD , Director of the Ivy Brain Tumor Center and Director of Neurosurgical Oncology at Barrow Neurological Institute, presented the findings during an oral session on CNS tumors at the European Society for Medical Oncology Congress in Paris today.
  • The initial results of this Phase 0 study of pamiparib plus radiotherapy are the first of its kind, said Dr. Sanai.
  • Follow the Ivy Brain Tumor Center on Facebook , Instagram , Twitter , and LinkedIn .

Global Advanced Gastric Carcinoma Pipeline Insights Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, October 4, 2021
Health, Oncology, News, Clinical trial, BeiGene, Mergers and acquisitions, II, SHR, Therapy, III, Stomach, Jiangsu Hengrui Medicine, PARP inhibitor, PARP2, HR, PARP1, Cancer, Discovery, Pharmaceutical industry, Coffee

The "Advanced Gastric Carcinoma - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Advanced Gastric Carcinoma - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This Advanced Gastric Carcinoma - Pipeline Insight, 2021 report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced Gastric Carcinoma pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Advanced Gastric Carcinoma R&D.
  • This segment of the report provides insights about the different Advanced Gastric Carcinoma drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.

Global HR+/HER2-VE Breast Cancer Pipeline Landscape Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 28, 2021
Pharmaceutical, Health, Oncology, Phase II, News, Clinical trial, BeiGene, II, Breast cancer, Therapy, III, PARP inhibitor, Acquisition, PARP2, Breast, PARP1, Cancer, Discovery, Medical imaging, Pharmaceutical industry

The "HR+/HER2-VE Breast Cancer - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "HR+/HER2-VE Breast Cancer - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This HR+/HER2-VE Breast Cancer - Pipeline Insight, 2021 provides comprehensive insights about 40+ companies and 50+ pipeline drugs in HR+/HER2-VE Breast Cancer pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence HR+/HER2-VE Breast Cancer R&D.
  • The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging HR+/HER2-VE Breast Cancer drugs.

Global Gastric Cancer Pipeline Landscape Report 2021 - Comprehensive Insights About 100+ Companies and 100+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 28, 2021
Pharmaceutical, Health, Oncology, News, Clinical trial, Mergers and acquisitions, II, Therapy, III, NMPA, Marketing, PARP inhibitor, Acquisition, PARP2, PD-1, PARP1, Enzyme, Discovery, Dietary supplement, Pharmaceutical industry, Vaccine

This Gastric Cancer - Pipeline Insight, 2021 provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Gastric Cancer pipeline landscape.

Key Points: 
  • This Gastric Cancer - Pipeline Insight, 2021 provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Gastric Cancer pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Gastric Cancer R&D.
  • This segment of the Gastric Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.
  • The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gastric Cancer drugs.

Onxeo Receives Notice of Allowance for a New Patent Broadening the Protection of AsiDNA™ in combination with a PARP Inhibitor in the United States

Retrieved on: 
Wednesday, June 9, 2021
Branches of biology, Biology, DNA repair, Cellular processes, Senescence, PARP inhibitor, Programmed cell death, Homologous recombination, PARP1, Poly (ADP-ribose) polymerase

This new patent completes, in a key territory, the already robust patent family protecting AsiDNA in combination with PARP inhibitors.

Key Points: 
  • This new patent completes, in a key territory, the already robust patent family protecting AsiDNA in combination with PARP inhibitors.
  • The DNA repair pathways, BRCA-dependent homologous recombination pathway and PARP pathway, are complementary and essential for tumor cell survival and proliferation.
  • If one pathway is deficient (homologous recombination by BRCA mutation) and the other is blocked by a PARP inhibitor, the tumor cell dies.
  • "This patent represents a further recognition in the strategic US market of the very original properties of AsiDNA.

Repare Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results

Retrieved on: 
Thursday, May 13, 2021
FDA, Health, Clinical trials, General Health, Pharmaceutical, Biotechnology, Communication, Forward-looking statement, PARP inhibitor, XC2, Repare Therapeutics’ SNIPRx® Platform, Repare Therapeutics, Inc., REPARE THERAPEUTICS’ SNIPRX® PLATFORM, REPARE THERAPEUTICS, INC.

The PARP inhibitor and RP-3500 combination arm is now recruiting,\xe2\x80\x9d said Lloyd M. Segal, President and Chief Executive Officer of Repare.

Key Points: 
  • The PARP inhibitor and RP-3500 combination arm is now recruiting,\xe2\x80\x9d said Lloyd M. Segal, President and Chief Executive Officer of Repare.
  • For more information, please visit reparerx.com.\nSNIPRx\xc2\xae is a registered trademark of Repare Therapeutics Inc.\nThis press release contains \xe2\x80\x9cforward-looking statements\xe2\x80\x9d within the meaning of the Private Securities Litigation Reform Act of 1995.
  • These forward-looking statements are based on the Company\xe2\x80\x99s expectations and assumptions as of the date of this press release.
  • The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.\n'

China NMPA Approves PARP Inhibitor Pamiparib for Patients with Previously Treated Advanced Ovarian Cancer

Retrieved on: 
Friday, May 7, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Oncology, Gynaecological cancer, PARP inhibitor, Ovarian cancer, Gynecologic oncology, Medical specialties, Health, Orphan drugs, Clinical medicine, Ovarian Cancer, Pamiparib, the Pamiparib Clinical Program, BeiGene, OVARIAN CANCER, PAMIPARIB, THE PAMIPARIB CLINICAL PROGRAM, BEIGENE

BeiGene will continue working to advance our broad, diverse pipeline and executing on our mission of expanding access to and improving affordability of impactful treatments for patients worldwide.\xe2\x80\x9d\n\xe2\x80\x9cWe are thrilled that pamiparib is the first PARP inhibitor approved in China for patients with both platinum-sensitive and platinum-resistant relapsed ovarian cancer.

Key Points: 
  • BeiGene will continue working to advance our broad, diverse pipeline and executing on our mission of expanding access to and improving affordability of impactful treatments for patients worldwide.\xe2\x80\x9d\n\xe2\x80\x9cWe are thrilled that pamiparib is the first PARP inhibitor approved in China for patients with both platinum-sensitive and platinum-resistant relapsed ovarian cancer.
  • \xe2\x80\x9cWe appreciate the patients and investigators who participated in this trial, and hope that pamiparib will become an important treatment option for patients in China with recurrent ovarian cancer.
  • The encouraging pivotal Phase 2 data demonstrated that pamiparib can provide clinically meaningful and durable responses for patients who are sensitive or resistant to platinum-based chemotherapy.
  • CA Cancer J Clin, 2016;66(2):115-132.\nv Jiang X, Tang H, Chen T. Epidemiology of gynecologic cancers in China.

Repare Therapeutics to Highlight Program Progress for RP-6306 at Today’s Virtual Investor Day Event

Retrieved on: 
Thursday, April 8, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Genetics, Synthetic lethality, Cancer, PARP inhibitor, Draft:RA Myc associated synthetic lethality, Biotechnology, RP-6306, Repare Therapeutics, Inc.

ET, highlighting the progress of its proprietary RP-6306 program for tumors with genetic alterations characterized by CCNE1 amplification.

Key Points: 
  • ET, highlighting the progress of its proprietary RP-6306 program for tumors with genetic alterations characterized by CCNE1 amplification.
  • The incidence of such cancers is rising and represents a growing therapeutic challenge, said Maria Koehler, MD, PhD, Chief Medical Officer of Repare.
  • Targeting DNA damage repair using synthetic lethal strategies is a massive opportunity to build on the success of PARP inhibitors.
  • Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics.

Gradalis Announces Publication of Phase 2b VITAL trial of Vigil® demonstrating RFS and OS advantage in women with first-line platinum-responsive BRCA1 and BRCA2 wild-type advanced ovarian cancer in The Lancet Oncology

Retrieved on: 
Thursday, January 7, 2021
Cancer, Breast cancer, Ovarian cancer, Branches of biology, Health, Gynaecology, BRCA1, BRCA mutation, BRCA, HRDetect, PARP inhibitor

Importantly overall survival was also significantly longer for Vigil treated ovarian cancer patients with BRCA1/2-wt disease compared to placebo.

Key Points: 
  • Importantly overall survival was also significantly longer for Vigil treated ovarian cancer patients with BRCA1/2-wt disease compared to placebo.
  • As ovarian cancer is becoming increasingly molecularly annotated for BRCA mutations, identifying effective treatment options for women whose tumors are BRCA1/2-wt is a priority.
  • Vigil is being studied in Ovarian cancer, Ewings sarcoma as well as gynecological cancers and advanced womens cancer in combination with PD-L1 inhibitors.
  • We utilized the bi-shRNA platform to develop Vigil, our proprietary personalized cancer in multiple advanced cancer indications with the lead program for the treatment of patients with Ovarian Cancer.

LYNPARZA® (olaparib) Receives Three New Approvals in Japan

Retrieved on: 
Monday, December 28, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Life sciences, Medicine, Health sciences, PARP inhibitor, Biomarker, AstraZeneca, PAOLA-1, PROfound, POLO, LYNPARZA® (olaparib), BRCA Mutations, Homologous Recombination Deficiency, the AstraZeneca and Merck Strategic Oncology Collaboration, Merck

Dave Fredrickson, executive vice president, oncology business unit, AstraZeneca, said, These three approvals allow patients in Japan to be treated with LYNPARZA, a targeted treatment personalized to their specific biomarkers.

Key Points: 
  • Dave Fredrickson, executive vice president, oncology business unit, AstraZeneca, said, These three approvals allow patients in Japan to be treated with LYNPARZA, a targeted treatment personalized to their specific biomarkers.
  • LYNPARZA is the first and only PARP inhibitor approved in Japan in this disease.
  • In patients with moderate renal impairment (CLcr 31-50 mL/min), reduce the dose of LYNPARZA to 200 mg twice daily.
  • Dose interruptions due to an AR occurred in 45% of patients receiving LYNPARZA and dose reductions due to an AR occurred in 22% of LYNPARZA patients.